Hologic (NASDAQ:HOLX) is a global medical technology company focused on women’s health, diagnostics, and medical imaging. The company develops, manufactures, and supplies a broad portfolio of products designed to improve clinical outcomes and enhance efficiency in healthcare settings. Its principal offerings include mammography systems, minimally invasive surgical devices for gynecologic applications, diagnostic tests for infectious diseases and oncology, and bone densitometry systems for skeletal health assessment.
Founded in 1985, Hologic has grown through strategic research and development initiatives as well as targeted acquisitions, such as the purchase of Cytyc Corporation and Gen-Probe. These transactions expanded its capabilities in cervical cancer screening, molecular diagnostics, and tissue management solutions. Today, Hologic serves customers in more than 100 countries, with a strong presence in North America, Europe, Asia-Pacific, and Latin America. The company’s global distribution network includes direct sales forces, distributors, and service centers, enabling it to support healthcare providers in hospitals, diagnostic laboratories, imaging centers, and physician offices.
Hologic places a strong emphasis on innovation, investing in advanced imaging technologies such as 3D mammography and molecular assays designed to deliver faster, more accurate results. Its R&D efforts align with emerging healthcare trends, including personalized medicine and point-of-care testing. Under the leadership of President and Chief Executive Officer Stephen P. MacMillan, Hologic continues to expand its pipeline of novel products and to pursue strategic partnerships that enhance its diagnostic and therapeutic offerings. The company’s commitment to women’s health extends beyond product development, encompassing educational programs, community outreach, and collaborative research endeavors aimed at reducing the global burden of disease.
